A very small study showed promising results with a drug that's similar to the Sanofi and Regeneron drug, called Kevzara, that treats arthritis. Several patients in the study “got out of death’s bed and walked out of the hospital” after receiving Actemra, said a Regeneron scientist. The race for a treatment has sent pharma into a tizzy to be the first to strike on something that works. Meanwhile, other labs are working on creating an effective vaccine.
from Kaiser Health News https://ift.tt/33klDS9
March 11, 2020
Rose
Health News, Kaiser Health News
No comments
Related Posts:
Sickened By Billing Abuses, Readers And Tweeters Stand Up For Patients’ RightsLetters to the Editor is a periodic feature. We welcome all comments and will publish a selection. We edit for length and clarity and require full names. Private Equity Predators? First of all, let me thank you for… Read More
EPA Steps Up Threats About Problems In California, Adding Water Pollution To List Of Other IssuesThe Trump administration and California are in an escalating fight over a range of issues, including homelessness, the environment and immigration. Yesterday, a letter from EPA administrator Andrew Wheeler gave Gov. Gavin New… Read More
KHN Files Lawsuit To Force Feds To Disclose Medicare Advantage AuditsKaiser Health News is suing the U.S. Centers for Medicare & Medicaid Services to release dozens of audits that the agency says reveal hundreds of millions of dollars in overcharges by Medicare Advantage health plans. The … Read More
NIH Awards $945M For Research On Treating Chronic Pain, Opioid AddictionNational Institutes of Health Director Francis S. Collins says the grant “represents the urgency of this crisis.” In other news, the inspector general at the Department of Health and Human Services says NIH should set up bett… Read More
First Edition: September 27, 2019Today's early morning highlights from the major news organizations. from Kaiser Health News https://ift.tt/2lF8otM … Read More
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment